Voriconazole: Invasive aspergillosis: Benifits to be confirmed

Prescrire International

Volumn 13, Issue 69, 2004, Pages 13-16

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIURETIC AGENT; ERGOT ALKALOID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ISOENZYME; ITRACONAZOLE; LAXATIVE; LIVER ENZYME; PIMOZIDE; PYRROLE DERIVATIVE; QUINIDINE; RAPAMYCIN; RIFAMPICIN; SULFONYLUREA; SULTOPRIDE; TACROLIMUS; VORICONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANAPHYLACTIC SHOCK; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG INDICATION; DRUG INFUSION; DRUG MARKETING; ENZYME INHIBITION; ERGOTISM; ERYTHEMA; ERYTHRODERMA; FUSARIUM; HALLUCINATION; HEADACHE; HEART ARREST; HEART ATRIUM ARRHYTHMIA; HEART DISEASE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; PHOTOPHOBIA; PHOTOSENSITIZATION; QT PROLONGATION; RASH; REVIEW; SCEDOSPORIUM; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; SURVIVAL; TERATOGENICITY; TORSADE DES POINTES; VASOMOTOR DISORDER; VISUAL DISORDER; ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG INTERACTION; IMMUNE DEFICIENCY; MYCETOMA; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DRUG INTERACTIONS; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; MADUROMYCOSIS; MYCOSES; PYRIMIDINES; SCEDOSPORIUM; TREATMENT OUTCOME; TRIAZOLES;

EID: 1042303573     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Prescrire Editorial Staff "Caspofungin" Prescrire Int 2002; 11 (61): 142-143.
2. Ruhnke M and Maschmeyer G "Management of mycosis in patients with hematologic disease and cancer - Review of the litterature" Eur J Med Res 2002;7: 227-235.
3. Prescrire Rédaction "amphotéricine B liposomale. AmBisome°: un recours pour des infections graves"; full article (5 pages, 26 references) supplement to Rev Prescrire 1999; 19 (200): 745.
4. Prescrire Editorial Staff "Itraconazole" Prescrire Int 1994; 3 (10): 34-37.
5. Prescrire Rédaction "Nouvelle indication. Abelcet°" et candidoses systémiques" Rev Prescrire 2001; 21 (214):120
6. Bennett JE "Miscellaneous Mycoses and algal infections". In: Brauwald E et al. "Harrison's principles of internal medicine" 15th ed., Mc Graw-Hill, New York 2001: 1180-1185.
7. Ghannoum MA and Kuhn DM "Voriconazole-better chances for patients with invasive mycosis" Eur J Med Res 2002; 7: 242-256.
8. Espinel-Ingroff A et al. "In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature" Mycopathologia 2001; 150: 101-115.
9. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report (EPAR): VFend (Voriconazole)" London 3 April 2002; 161 pages.
10. Herbrecht R et al. "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis" N Engl J Med 2002; 347 (6): 408-415 + 347 (25): 2080-2081.
11. Denning DW et al. "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis" Clin Infect Dis 2002; 34: 563-571.
12. Pfizer "Briefing document for voriconazole" 4 October 2001: 99 pages.
13. Ally R et al. "A randomized, double-blind, double-dummy multicentre trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients" Clin Infect Dis 2001; 33 (9): 1447-1454.
14. Tomaszewski K et al. "The overall clinical safety of voriconazole" Annual Meeting of the American Society for Blood and Bone Marrow Transplantation, Orlando 2002; abstr.: 1 page.
15. Walsh TJ et al. "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever" N Engl J Med 2002; 346 (4): 225-234 + 346 (19): 1499 + 346 (22): 1745-1747.
16. Food and Drug Administration "Vfend°" Summary of the product's characteristics" 28 March 2003: 34 pages.
17. Prescrire Rédaction "Insuffisance cardiasque sous itraconazole" Rev Prescrire 2001; 21 (219): 514.
18. French datasheet compendium "Antifongiques". In: "Interactions Médicamenteuses" Vidal, Paris 2003: 49-52.
19. Powers JH et al. "Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever" N Engl J Med 2002; 346 (4): 289-290.